TERAPIA DE REEMPLAZO HORMONAL Y RIESGO DE DEMENCIA

TERAPIA DE REEMPLAZO HORMONAL Y RIESGO DE DEMENCIA

(especial para SIIC © Derechos reservados)
Evaluación de la información reciente y discusión de posibles explicaciones y mecanismos relacionados con el riesgo de demencia en las pacientes que reciben terapia de reemplazo hormonal.
levinean9.jpg Autor:
Andrew J. Levine
Columnista Experto de SIIC

Institución:
Department of Psychiatry and Biobehavioral Science UCLA School of Medicine


Artículos publicados por Andrew J. Levine
Coautor
Karen Miller, Ph.D* 
UCLA School of Medicine. Department of Psychiatry and Biobehavioral Science.*
Recepción del artículo
6 de Diciembre, 2004
Aprobación
28 de Diciembre, 2004
Primera edición
11 de Octubre, 2005
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
La terapia de reemplazo hormonal (TRH) ha recibido apoyo generalizado como medida preventiva para la enfermedad de Alzheimer (EA). Sin embargo, estudios recientes indican que la TRH en realidad puede aumentar el riesgo de EA y de otras enfermedades neurodegenerativas en determinadas poblaciones. En el presente informe, revisamos estudios recientes, discutimos explicaciones y mecanismos posibles del aumento del riesgo observado y señalamos vías potenciales para la investigación futura.

Palabras clave
Terapia de reemplazo hormonal (TRH), estrógeno, progestina, demencia, enfermedad de Alzheimer, demencia frontotemporal


Artículo completo

(castellano)
Extensión:  +/-6.98 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Hormone replacement therapy (HRT) has received widespread support as a preventative measure for Alzheimer’s disease (AD). However, recent studies have indicated that HRT may in fact raise the risk of AD and other neurodegenerative diseases in certain populations. In the current paper, we review these recent studies, discuss possible explanations and mechanisms for the observed increase in risk, and point out potential avenues for future research.

Key words
Hormone replacement therapy (HRT), estrogen, progestin, dementia, Alzheimer’s disease, frontotemporal dementia


Full text
(english)
para suscriptores/ assinantes

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Obstetricia y Ginecología
Relacionadas: Atención Primaria, Bioética, Bioquímica, Endocrinología y Metabolismo, Farmacología, Medicina Familiar, Medicina Farmacéutica, Medicina Interna, Salud Mental



Comprar este artículo
Extensión: 6.98 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra




Patrocinio y reconocimiento:
La beca de investigación del Dr. Levine (T-32 MH19535) es financiada por el NIMH. Un agradecimiento especial a Sarah Spina por su arduo trabajo.
Bibliografía del artículo
  1. Brinton, RD, Tran, J, Profitt, P et al. 17 Beta-estradiol increases the growth and survival of cultured cortical neurons. Neurochem Res 1997; 22:1339-1351.
  2. Gould, E, Woolley, CS, Frankfurt, M et al. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci 1999; 10(4):1286-1291.
  3. Luine, VN. Estradiol increases acetyltransferase activity in specific basal forebrain nuclei and projection areas of the female rat brain. Exp Neurol 1985; 89:484-490.
  4. Rabbani, O, Panickar, KS, Rajakumar, G et al. 17 Beta-estradiol attenuates fimbrial lesion-induced decline of ChAT-immunoreactive neurons in the rat medial septum. Exp Neurol 1997; 146, 179-186.
  5. Small, GW. Estrogen effects on the brain. J Gend Specif Med 1998; 1:23-27.
  6. LeBlanc, ES, Janowsky, J, Chan, BKS et al. Hormone replacement therapy and cognition: Systematic review and meta-analysis. JAMA 2001; 285:1489-1499.
  7. Miller, KJ, Conney, JC, RAsgon, NL et al. Mood symptoms and cognitive performance in women estrogen users, non-users, and men. JAGS 2002; 50(11): 1826-1830.
  8. Yaffe, K, Sawaya, G, Lieberburg, I et al. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA 1998; 279: 688-695.
  9. Maki, PM, Resnick, SM. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiology of Aging 2000; 21(2): 373-383.
  10. Rasgon, NL, Silverman, D, Siddarth, P et al. Estrogen use and brain metabolic change in postmenopausal women. Neurobiology of Aging, 2004.
  11. Rasgon, NL, Small, GW, Siddarth, P et al. Estrogen use and brain metabolic change in older adults. A preliminary report. Psychiatric Research: Neuroimaging 2001; 107:11-18.
  12. Brinton, RD, Yamazaki, RS. Advances and challenges in the prevention and treatment of Alzheimer’s disease. Pharm Res 1998; 15(3):386-398.
  13. Monk, D, Brodaty, H. Use of estrogens for the prevention and treatment of Alzheimer’s disease. Dementia and the Geriatric Cognitive Disorders 2000; 11:1-10.
  14. Nelson, HD, Humphrey, LL, Nygren, P et al. Postmenopausal hormone replacement: Scientific review. JAMA 2002; 288:872-881.
  15. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288:321-333.
  16. Writing Group for the Women’s Health Initiative Investigators. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291:1701-1712.
  17. Rapp, SR, Espeland, MA, Schumaker, SA et al. Effects of estrogen plus progestin on global cognitive function in postmenopausal women. JAMA 2003; 289(20):2663-2672.
  18. Epseland, MA, Rapp, SR, Schumaker SA et al. Conjugated equine estrogens and global cognitive function in postmenopausal women. JAMA 2004; 291(24): 2959-2968.
  19. Schumaker, SA, Legault, C, Kuller, L et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. JAMA 2004; 291(24):2947-2958.
  20. Levine, A, Hewett, L. Estrogen replacement therapy and Frontotemporal Dementia. Maturitas 2003; 45:83-88.
  21. Popat, RA, Van Den Eden, SK, Tanner, CM et al. Effect of exogenous and endogenous estrogen on the risk of Parkinson’s disease. Neurology 2002; 58:A83.
  22. Currie, LJ, Harrison, MB, Trugman, JM et al. Postmenopausal estrogen use affects risk for Parkinson’s disease. Archives of Neurology 2004; 61:886-888.
  23. Shulman, LM. Is there a connection between estrogen and Parkinson’s disease Parkinsonism and Related Disorders 2002; 8:289-295.
  24. Neary, D, Snowden, JS, Gustafson, L et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 1998; 51:1546-1554.
  25. The Lund and Manchester Groups. Consensus statement. Neropathological criteria for fronto-temporal dementia. J Neurol Neurosurg Psychiatry 4: 416-418.
  26. Tolany, M, Probst, A. Frontotemporal lobar degeneration. Gerontology 2001; 47:1-8.
  27. Giasson, BI, Wilson, CA, Trojanowski, JQ et al. Tau and alpha-synuclein dysfunction in neurodegenerative diseases. In: Chesselet, M-F and Totowa, MJ (eds.). Contemporary clinical neuroscience: Molecular mechanisms of neurodegenerative diseases. Humana Press.
  28. Hardy, J. Pathways to primary neurodegenerative disease. Mayo Clinic Proceedings 1999; 74:835-7.
  29. Lew, GM. Changes in microtubule tau protein after estrogen in a cultured human neuroblastoma cell line. Gen Pharmac 1993; 25(6):1383-1386.
  30. Ferreira, A, Caceres, A. Estrogen-enhanced neurite growth: Evidence for a selective induction of tau and stable microtubules. The Journal of Neuroscience 1991; 11(2):392-400.
  31. Brinton, RD. Impact of estrogen therapy on Alzheimer’s disease: A fork in the road CNS Drugs 2004; 18(7):405-422.
  32. Nilsen, J, Brinton, RD. Impact of progestins on estrogen-induced neuroprotection: Synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 2002; 143(1):205-212.
  33. Shoghi-Jadid, K, Small, GW, Agdeppa, ED et al. Localization of neurofibrillary tangles (NFTs) and beta-amyloid plaques (APs) in the brains of living patients with Alzheimer’s disease. American Journal of Geriatric Psychiatry 2002; 10: 24-35.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618